These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2950616)

  • 1. Plasma levels of maprotiline and zimelidine and their relationship to clinical response in depressed patients.
    Hrdina PD; Lapierre YD
    Ther Drug Monit; 1986; 8(4):400-6. PubMed ID: 2950616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Blood concentrations of maprotiline in depressive patients].
    Rouillon F; Sioufi A; Serrurier D; Mizon JP; Plaquet R; Richard JB; Riche C; Bourin M; Kergueris MF; Besançon G
    Encephale; 1988; 14(4):299-305. PubMed ID: 3058453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of zimelidine using a new GLC method.
    Caillé G; Kouassi E; de Montigny C
    Clin Pharmacokinet; 1983; 8(6):530-40. PubMed ID: 6228368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maprotiline in affective illness. Plasma concentration and clinical response.
    Norman TR; Burrows GD; Maguire KP; McIntyre IM; Scoggins BA
    J Affect Disord; 1983 May; 5(2):147-54. PubMed ID: 6222094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antidepressant efficacy of zimelidine and maprotiline.
    Montgomery SA; Rani SJ; McAuley R; Roy D; Montgomery DB
    Acta Psychiatr Scand Suppl; 1981; 290():219-24. PubMed ID: 6452792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to maprotiline treatment in depressive patients relationship to urinary MHPG excretion and plasma drug level.
    Gaertner HJ; Golfinopoulos G; Breyer-Pfaff U
    Pharmacopsychiatria; 1982 Sep; 15(5):170-4. PubMed ID: 7178231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of maprotiline and its adverse effects on depressed patients.
    Kurata K; Kido H; Hasegawa M; Inoue M; Yamaguchi N
    Jpn J Psychiatry Neurol; 1987 Jun; 41(2):247-54. PubMed ID: 3437612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zimelidine vs maprotiline in depressed outpatients. A preliminary report.
    d'Elia G; Hällström T; Nyström C; Ottosson JO
    Acta Psychiatr Scand Suppl; 1981; 290():225-35. PubMed ID: 6452793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. Biochemical aspects.
    Nyström C; Ross SB; Hällström T; Kelder D
    Acta Psychiatr Scand; 1986 Feb; 73(2):133-8. PubMed ID: 2939691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. A preliminary study.
    Møller SE; de Beurs P; Timmerman L; Tan BK; Leijnse-Ybema HJ; Stuart MH; Petersen HE
    Psychopharmacology (Berl); 1986; 88(1):96-100. PubMed ID: 3080781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials with new bicyclic and tetracyclic compounds: zimelidine and maprotiline [proceedings].
    Claghorn JL; Mathew RJ
    Psychopharmacol Bull; 1981 Jan; 17(1):23-6. PubMed ID: 6453355
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison of maprotiline and its desmethylated metabolite serum concentrations in outpatients and inpatients.
    Kurata K; Kido H; Hasegawa M; Inoue M; Yamaguchi N
    Jpn J Psychiatry Neurol; 1987 Jun; 41(2):255-60. PubMed ID: 3437613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maprotiline versus imipramine and placebo in neurotic depression.
    van der Velde CD
    J Clin Psychiatry; 1981 Apr; 42(4):138-41. PubMed ID: 7009592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled cross-over study of a 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant.
    Aberg A
    Acta Psychiatr Scand Suppl; 1981; 290():244-55. PubMed ID: 6452794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic superiority of maprotiline versus doxepin in geriatric depression.
    Gwirtsman HE; Ahles S; Halaris A; DeMet E; Hill MA
    J Clin Psychiatry; 1983 Dec; 44(12):449-53. PubMed ID: 6361005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma-level response relationships with fluoxetine and zimelidine.
    Montgomery SA; Baldwin D; Shah A; Green M; Fineberg N; Montgomery D
    Clin Neuropharmacol; 1990; 13 Suppl 1():S71-5. PubMed ID: 2143100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between blood concentrations and clinical effects of a new antidepressant "maprotiline".
    Watanabe S; Yokoyama S; Kubo S; Iwai H; Kuyama C
    Folia Psychiatr Neurol Jpn; 1980; 34(2):147-56. PubMed ID: 7007180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of maprotiline and desmethylmaprotiline in plasma and urine by gas chromatography with nitrogen-phosphorus detection.
    Drebit R; Baker GB; Dewhurst WG
    J Chromatogr; 1988 Nov; 432():334-9. PubMed ID: 3220903
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects.
    Kasper S; Dötsch M; Kick H; Vieira A; Möller HJ
    Eur Neuropsychopharmacol; 1993 Mar; 3(1):13-21. PubMed ID: 8471827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind study comparing paroxetine and maprotiline in depressed outpatients.
    Szegedi A; Wetzel H; Angersbach D; Dunbar GC; Schwarze H; Philipp M; Benkert O
    Pharmacopsychiatry; 1997 May; 30(3):97-105. PubMed ID: 9211571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.